Since high EGFR expression is seen in about 87% of patients with PC, and also reflected in the present study, the combination of licofelone and gefitinib reduced COX-2, 5-LOX, EGFR, DclK1, mPGES-1, mPGES-2, FLAP, and β-catenin, and increased p21 expression, compared with untreated controls and animals treated with either drug alone. The gene discussed is EGFR; the disease is pachyonychia congenita.